GoldBamboo.com - Knowledge is strong medicine
  

Study Evaluating Levonorgestrel/Ethinyl Estradiol (LNG/EE) in PMS - Article


  Not Signed In - Sign In / Register




General Topics A-Z

Premenstrual Syndrome

Premenstrual Syndrome (PMS); Premenstrual Syndrome / Pms

Clinical Trial: Study Evaluating Levonorgestrel/Ethinyl Estradiol (LNG/EE) in PMS

This study is currently recruiting patients.
Verified by Wyeth September 2005

Sponsored by: Wyeth
Information provided by: Wyeth
ClinicalTrials.gov Identifier: NCT00161681

Purpose

The purpose of this study is to determine whether LNG/EE is effective in the treatment of menstrual cycle related symptoms.
Condition Intervention Phase
Premenstrual Syndrome
  Drug: Levonorgestrel/Ethinyl Estradiol
 Phase III

MedlinePlus related topics:  Premenstrual Syndrome

Study Type: Interventional
Study Design: Prevention, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study

Official Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Levonorgestrel 90 Mcg and Ethinyl Estradiol 20 Mcg in a Continuous Daily Regimen on Menstrual Cycle-Related Symptoms

Further Study Details: 
Primary Outcomes: To evaluate the efficacy of a continuous-use oral contraceptive regimen containing a combination of LNG/EE in preventing moderate to severe menstrual cycle-related symptoms compared with placebo.
Secondary Outcomes: To evaluate the effects of this LNG/EE regimen on work productivity and subject satisfaction.
Expected Total Enrollment:  200

Study start: August 2005

Eligibility

Ages Eligible for Study:  18 Years   -   49 Years,  Genders Eligible for Study:  Female
Criteria

Inclusion Criteria:

  • Healthy women aged 18 to 49 years
  • Regular 21 to 35 day menstrual cycles for 3 months prior to study visit 1
  • History of menstrual cycle related symptoms as determined by the investigator.

Exclusion Criteria:

  • Contraindication to combination oral contraceptives
  • Depression requiring hospitalization or associated with suicidal ideation within the last 3 years
  • Use of antidepressants/anxiolytics within 10 days of screening and for the duration of the study.

Location and Contact Information

Please refer to this study by ClinicalTrials.gov identifier  NCT00161681

Trial Manager       clinicaltrialinfo@wyeth.com

Alabama
      Huntsville,  Alabama,  35801,  United States; Not yet recruiting
see Central Contact

Arizona
      Tucson,  Arizona,  85715,  United States; Not yet recruiting
see Central Contact

      Phoenix,  Arizona,  85031,  United States; Not yet recruiting
see Central Contact

      Phoenix,  Arizona,  85032,  United States; Recruiting
see Central Contact

      Peoria,  Arizona,  85381,  United States; Not yet recruiting
see Central Contact

California
      San Diego,  California,  92103,  United States; Not yet recruiting
see Central Contact

Colorado
      Longmont,  Colorado,  80501,  United States; Recruiting
see Central Contact

      Denver,  Colorado,  80202,  United States; Recruiting
see Central Contact

Florida
      Boynton Beach,  Florida,  33437,  United States; Not yet recruiting
see Central Contact

      Miami,  Florida,  33143,  United States; Not yet recruiting
see Central Contact

      Miami,  Florida,  33186,  United States; Recruiting
see Central Contact

      Aventura,  Florida,  33180,  United States; Not yet recruiting
see Central Contact

      West Palm Beach,  Florida,  33407,  United States; Recruiting
see Central Contact

      Pembroke Pines,  Florida,  33024,  United States; Not yet recruiting
see Central Contact

      Deland,  Florida,  32720,  United States; Not yet recruiting
see Central Contact

      Clearwater,  Florida,  33761,  United States; Not yet recruiting
see Central Contact

      Tampa,  Florida,  33607,  United States; Not yet recruiting
see Central Contact

      Fort Myers,  Florida,  33916,  United States; Not yet recruiting
see Central Contact

Georgia
      Atlanta,  Georgia,  30328,  United States; Not yet recruiting
see Central Contact

      Atlanta,  Georgia,  30342,  United States; Not yet recruiting
see Central Contact

      Savannah,  Georgia,  31406,  United States; Recruiting
see Central Contact

Idaho
      Idaho Falls,  Idaho,  83404,  United States; Recruiting
see Central Contact

Illinois
      Chicago,  Illinois,  60631,  United States; Not yet recruiting
see Central Contact

      Chicago,  Illinois,  60612,  United States; Recruiting
see Central Contact

Kentucky
      Lexington,  Kentucky,  40509,  United States; Recruiting
see Central Contact

Missouri
      Kansas City,  Missouri,  64114,  United States; Not yet recruiting
see Central Contact

Nevada
      Las Vegas,  Nevada,  89109,  United States; Recruiting
see Central Contact

      Las Vegas,  Nevada,  89118,  United States; Recruiting
see Central Contact

New Jersey
      Moorestown,  New Jersey,  08057,  United States; Not yet recruiting
see Central Contact

New York
      Rochester,  New York,  14609,  United States; Not yet recruiting
see Central Contact

North Carolina
      Fayetteville,  North Carolina,  28304,  United States; Not yet recruiting
see Central Contact

      Winston Salem,  North Carolina,  27103,  United States; Not yet recruiting
see Central Contact

      Winston Salem,  North Carolina,  27103,  United States; Recruiting
see Central Contact

Ohio
      Mogadore,  Ohio,  44260,  United States; Not yet recruiting
see Central Contact

      Cleveland,  Ohio,  44122,  United States; Recruiting
see Central Contact

Oregon
      Eugene,  Oregon,  97401,  United States; Not yet recruiting
see Central Contact

      Medford,  Oregon,  97504,  United States; Not yet recruiting
see Central Contact

Pennsylvania
      Pittsburgh,  Pennsylvania,  15206,  United States; Not yet recruiting
see Central Contact

      Wexford,  Pennsylvania,  15090,  United States; Not yet recruiting
see Central Contact

      Philadelphia,  Pennsylvania,  19104,  United States; Recruiting
see Central Contact

South Carolina
      Hilton Head Island,  South Carolina,  29926,  United States; Recruiting
see Central Contact

      Mt. Pleasant,  South Carolina,  29464,  United States; Not yet recruiting
see Central Contact

Tennessee
      Nashville,  Tennessee,  37203,  United States; Not yet recruiting
see Central Contact

Texas
      Houston,  Texas,  77024,  United States; Not yet recruiting
see Central Contact

      San Antonio,  Texas,  78229,  United States; Not yet recruiting
see Central Contact

Utah
      Sandy,  Utah,  84070,  United States; Not yet recruiting
see Central Contact

Virginia
      Richmond,  Virginia,  23226,  United States; Not yet recruiting
see Central Contact

Washington
      Seattle,  Washington,  98105,  United States; Not yet recruiting
see Central Contact

      Lakewood,  Washington,  98499,  United States; Not yet recruiting
see Central Contact

Study chairs or principal investigators

Medical Monitor, MD,  Study Director,  Wyeth Research   

More Information

Study ID Numbers:  0858A2-322
Last Updated:  September 11, 2005
Record first received:  September 7, 2005
ClinicalTrials.gov Identifier:  NCT00161681
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-09-13


Source: ClinicalTrials.gov
Cache Date: September 14, 2005


Take control over your directory listings...INSTANTLY

Every day, thousands of users find businesses like yours in the GoldBamboo directory.

Limited Time Offer!!!

For only $50 a year, a savings of 50% off our standard rate:

  • Edit your listing (whenever you want!)
  • Link to your website
  • Choose which categories you are listed in
  • Describe your services

The process will take only a few minutes and consists of 3 easy steps:

1. Register     >     2. Edit Listings     >     3. Publish

Your Company
your street
yourtown, YS 12345
888-888-8888



No Thanks

Popular Treatments

Acne Treatment ADHD Treatment Allergy Treatment Alzheimer's Treatment
Anemia Treatment Arthritis Treatment Asthma Treatment Bipolar Disorder Treatment
Bird Flu Treatment Bladder Cancer Treatment Bladder Control Treatment Blood Pressure Treatment
Brain Tumor Treatment Breast Cancer Treatment Bronchitis Treatment Cancer Treatment
Cancer Alternative Treatment Cataract Treatment Cirrhosis Treatment Colitis Treatment
Colon Cancer Treatment Common Cold Treatment Conjunctivitis Treatment Constipation Treatment
Crohn's Disease Treatment Cystic Fibrosis Treatment Depression Treatment Dermatitis Treatment
Diabetes Treatment Edema Treatment Epilepsy Treatment Erectile Dysfunction Treatment
Fibromyalgia Treatment GERD Treatment Glaucoma Treatment Gout Treatment
Hay Fever Treatment Headache Treatment Heart Disease Treatment Hepatitis Treatment
High Blood Pressure Treatment High Cholesterol Treatment Hives Treatment Hypertension Treatment
Hypoglycemia Treatment IBS Treatment Impotence Treatment Indigestion Treatment
Infertility Treatment Influenza Treatment Insomnia Treatment Lactose Intolerance Treatment
Leukemia Treatment Lung Cancer Treatment Lyme Disease Treatment Macular Degeneration Treatment
Menopause Treatment Migraine Treatment Osteoarthritis Treatment Osteoporosis Treatment
Pancreatic Cancer Treatment PMS Treatment Pneumonia Treatment Prostate Diseases Treatment
Restless Leg Treatment Rheumatoid Arthritis Treatment Sepsis Treatment Sinusitis Treatment
Skin Cancer Treatment Sleep Apnea Treatment Snoring Treatment Stroke Treatment
Testicular Cancer Treatment
GoldBambooTM

Your Integrative Health and Wellness Resource for Premenstrual Syndrome.

July 26, 2008


Page Updated: October 3, 2005
Disclaimer: All material displayed on the GoldBamboo.com website is provided for educational purposes only. Consult a physician regarding the applicability of any information found on GoldBamboo.com to your symptoms or medical condition.

Insurance Quotes | Home | About Us | Link To Us | Feedback | Disclaimer | Privacy Policy | Terms of Use | Google Co-op | Health Forums

Copyright © 2004-2008 - Gold Bamboo LLC
All rights reserved.

HONcode accreditation seal.

We comply with the HONcode standard for health trust worthy information:
verify here.